Turning Point Therapeutics Announces Early Clinical Data For Novel MET Inhibitor TPX-0022 Selected For Late-Breaker Oral Presentation at 32nd EORTC-NCI-AACR Symposium

Matthew Durham
Omnidynamic Marketing

Frank Burrell
Scientific Storytelling

Stacey Gandler
Brand Nourishment

Daniel Sontupe
Market Access

Liz Kane
Impactful Strategy

David Linetsky
Point-of-Care Marketing

Matt Turner
Patient Affordability

Amy Giles
Increasing Engagement

Pat Purcell
Meeting Engagement

Bud Bilanich
Success Coach

Suma Ramadas, PhD
Medical Affairs

Joey Cohen
Medication Adherence

Brenda Snow
Authentic Patient Voice

Paul Theisen
Patient Acquisition